Skip to content Skip to sidebar Skip to footer
Subscribe Now
Viewpoint_Julie_Foster_2020
VIEWPOINTS
PharmaShots Interview: Medtronic’s Julie Foster Shares Insight on InPen Integrated with Guardian Connect CGM
In a recent interview with PharmaShots, Julie Foster, Vice President, Global Customer Experience of the Diabetes business at Medtronic, shares information about recent and upcoming announcements for the company. Shots: The integration of real-time CGM data into the smart insulin pen app follows the acquisition of Companion Medical's InPen to the Medtronic portfolio, as of Sept'2020 The…
December 2, 20200Comments
Viewpoint_Dr. David_Spetzler_2020
VIEWPOINTS
PharmaShots Interview: Caris Life Sciences’ Dr. Spetzler Shares Insight on AI-Powered Clinico-Genomic Data Platform
In a recent interview with PharmaShots, Dr. Spetzler, President and Chief Scientific Officer of Caris Life Sciences shared his insights and highlights on the launch of CODEai. Shots: CODEai is a real-world clinico-genomic data platform that integrates Caris Life Sciences extensive catalog of molecular data with cancer treatment information and clinical outcomes data for ~215,000…
December 1, 20200Comments
Viewpoint_Aidan_Foley_2020
VIEWPOINTS
PharmaShots Interview: True Digital Surgery’s Aidan Foley Shares Insight on the Aesculap Aeos Robotic Digital Microscope
In a recent interview with PharmaShots, Aidan Foley, Chairman and Chief Executive Officer of True Digital Surgery shared his insights and highlights on data of the Aesculap Aeos Robotic Digital Microscope. Shots: The robotic digital microscope enables surgeons to execute precision movements in neurosurgery, spine, and ear, nose, and throat operations, through a multi-axis robotic arm. The platform utilizes…
November 26, 20200Comments
Viewpoint_Dr. Eiry_Roberts_2020
VIEWPOINTS
PharmaShots Interview: Neurocrine’s Dr. Eiry Roberts Shares Insight on Ongentys (opicapone)
In a recent interview with PharmaShots, Dr. Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences shares her insights and highlights on data of Ongentys. Shots: In a post-hoc, sub-group analysis of the P-III BIPARK-1 study demonstrated greater reductions in overnight "off" time and time to morning "on" time compared to entacapone in patients with PD…
November 16, 20200Comments
Viewpoint_Douglas_Fambrough_2020
VIEWPOINTS
PharmaShots Interview: Dicerna’s Doug Fambrough Shares Insight on Nedosiran Data Presented at ASN Week 2020
In a recent interview with PharmaShots, Doug Fambrough, Ph.D., President and CEO of Dicerna shares his insights and highlights on data of Nedosiran presented at ASN Week 2020. Shots: All participants regardless of PH subtype, achieved normal or near-normal Uox excretion @day180, 92% participants (100% & 67% with PH1 & PH2) achieved normal Uox excretion…
November 9, 20200Comments